Chikungunya vaccines are vaccines intended to provide acquired immunity against the chikungunya virus. ^{[9] [11]} As of 2025 ^[update] , two vaccines have been licensed in some countries. These are Ixchiq, a live attenuated vaccine from Valneva, and Vimkunya manufactured by Bavarian Nordic which utilises virus-like particle technology. ^{[16] [17] [12] [14]}

Contents

• Medical uses
• History
• References

The most commonly reported side effects of Ixchiq include tenderness at the injection site, as well as headache, fatigue, muscle pain, joint pain, fever, and nausea. ^[17] However the license for Ixchiq has been suspended or restricted in some countries due to the risk of severe side effects, particularly in older people. ^{[18] [19]}

Medical uses

The chikungunya vaccine is indicated for the prevention of disease caused by chikungunya virus. ^{[8] [10]}

History

In November 2023, the US Food and Drug Administration (FDA) granted the application for the chikungunya vaccine with fast track, breakthrough therapy, and priority review designations. ^[17] The vaccine, Ixchiq, was licensed to Valneva Austria GmbH. ^{[17] [20]} It contains the live attenuated chikungunya virus (CHIKV) Δ5nsP3 strain of the ECSA/IOL genotype. ^[12]

Ixchiq was authorized for medical use in the European Union in June 2024. ^{[12] [13]} A second vaccine, Vimkunya, manufactured by Bavarian Nordic, was authorized for medical use in the European Union in February 2025. ^{[14] [15]}

References